Redhill Biopharma Valuation
| RDHL Stock | USD 2.80 0.04 1.45% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Redhill Biopharma holds a recent Real Value of $2.69 per share. The prevailing price of the company is $2.8. Our model determines the value of Redhill Biopharma from analyzing the company fundamentals such as Shares Owned By Institutions of 6.70 %, current valuation of (3.13 M), and Return On Equity of -17.09 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Redhill Biopharma's price fluctuation is very risky at this time. Calculation of the real value of Redhill Biopharma is based on 3 months time horizon. Increasing Redhill Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Redhill stock is determined by what a typical buyer is willing to pay for full or partial control of Redhill Biopharma. Since Redhill Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Redhill Stock. However, Redhill Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.8 | Real 2.69 | Hype 2.8 | Naive 3.4 |
The intrinsic value of Redhill Biopharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Redhill Biopharma's stock price.
Estimating the potential upside or downside of Redhill Biopharma helps investors to forecast how Redhill stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Redhill Biopharma more accurately as focusing exclusively on Redhill Biopharma's fundamentals will not take into account other important factors: Redhill Biopharma Total Value Analysis
Redhill Biopharma is at this time forecasted to have valuation of (3.13 M) with market capitalization of 3.71 M, debt of 1.17 M, and cash on hands of 28.86 M. The negative valuation of Redhill Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Redhill Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.13 M) | 3.71 M | 1.17 M | 28.86 M |
Redhill Biopharma Investor Information
The company recorded a loss per share of 292.52. Redhill Biopharma had not issued any dividends in recent years. The entity had 1:25 split on the 20th of August 2024. Based on the key measurements obtained from Redhill Biopharma's financial statements, Redhill Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Redhill Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Redhill Biopharma has an asset utilization ratio of 28.26 percent. This suggests that the Company is making $0.28 for each dollar of assets. An increasing asset utilization means that Redhill Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Redhill Biopharma Ownership Allocation
Roughly 93.3 pct. of Redhill Biopharma outstanding shares are held by general public with 6.7 (%) by third-party entities.Redhill Biopharma Profitability Analysis
The company reported the previous year's revenue of 6.51 M. Net Income was 23.92 M with profit before overhead, payroll, taxes, and interest of 1.26 M.About Redhill Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Redhill Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Redhill Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Redhill Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Redhill Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Redhill Biopharma. We calculate exposure to Redhill Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Redhill Biopharma's related companies.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biophrma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 201 people.
Redhill Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Redhill Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.5 M | |
| Forward Price Earnings | 1428.5714 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.